Analyst consensus rating
CorMedix Analyst Rating: Buy
Direct answer
CorMedix's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.80.
Forecast evidence checked November 17, 2026.
Get free CorMedix email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.82
- Average price target
- $13.80
- High price target
- $17.00
- Low price target
- $12.00
- Low target gap
- +149%
- Target upside
- +186.3%
- High target gap
- +252.7%
- Target range width
- 103.7%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- November 17, 2026
- Valid through
- November 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for CorMedix?
CorMedix has a verified Buy consensus. The same dataset has an average price target of $13.80.
How far are CorMedix's low and high targets from the recorded price?
The low target implies +149%, while the high target implies +252.7%.
How many analysts are included in CorMedix's consensus?
The verified consensus includes 5 analysts.
How is CorMedix's target upside or downside calculated?
The average target of $13.80 is divided by the recorded price of $4.82, then one is subtracted to produce +186.3%. This does not guarantee a future return.
When was CorMedix's analyst forecast verified?
The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.